27 August 2020 - Rocket’s fifth gene therapy program receives fast track designation.

Rocket Pharmaceuticals today announces that the U.S. FDA has granted fast track designation to RP-L401, the Company’s lentiviral vector based gene therapy for the treatment of infantile malignant osteopetrosis, a rare, severe monogenic bone resorption disorder characterised by skeletal deformities, neurologic abnormalities and bone marrow failure.

Read Rocket Pharmaceuticals press release